Investment House LLC Sells 14,934 Shares of Charles River Laboratories International, Inc. $CRL

Key Points

• Investment House LLC reduced its Charles River Laboratories (CRL) position by 62.2% in the third quarter, selling 14,934 shares and retaining 9,084 shares valued at approximately $2.68 million.
• Institutional investors own 98.91% of CRL, while company insiders sold 91,971 shares worth about $26.0 million over the prior three months.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $302.33 price target; CRL recently traded at $340.64 after beating quarterly earnings and revenue estimates.

Investment House LLC cut its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 62.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,084 shares of the medical research company's stock after selling 14,934 shares during the period. Investment House LLC's holdings in Charles River Laboratories International were worth $2,680,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CRL. Dimensional Fund Advisors LP raised its stake in Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock worth $285,001,000 after buying an additional 210,260 shares during the period. Bank of America Corp DE boosted its holdings in Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company's stock worth $195,792,000 after acquiring an additional 54,500 shares in the last quarter. Amundi boosted its holdings in Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company's stock worth $133,397,000 after acquiring an additional 492,301 shares in the last quarter. Van Berkom & Associates Inc. grew its stake in Charles River Laboratories International by 11.2% in the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company's stock valued at $86,449,000 after acquiring an additional 50,462 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in Charles River Laboratories International by 230.9% in the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company's stock valued at $59,044,000 after acquiring an additional 142,716 shares during the period. 98.91% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the transaction, the director directly owned 1,438 shares of the company's stock, valued at $410,175.12. The trade was a 28.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Victoria Creamer sold 4,179 shares of the company's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the sale, the executive vice president owned 30,051 shares of the company's stock, valued at approximately $7,788,017.16. The trade was a 12.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 91,971 shares of company stock worth $26,033,968 in the last three months. 1.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Barclays boosted their price objective on Charles River Laboratories International from $300.00 to $330.00 and gave the company an "overweight" rating in a report on Friday, September 25th. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Citigroup reissued a "buy" rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Sanford C. Bernstein set a $250.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Finally, UBS Group began coverage on shares of Charles River Laboratories International in a research note on Wednesday, September 30th. They issued a "buy" rating and a $357.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $302.33.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $340.64 on Friday. The firm has a market capitalization of $16.26 billion, a P/E ratio of -70.24, a P/E/G ratio of 3.22 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $146.20 and a 52 week high of $351.21. The stock has a 50 day moving average price of $293.05 and a two-hundred day moving average price of $232.43. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the company earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.